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Abstract
Background: Carcinomas of unknown primary (CUP) represent approximately 3%-5% of malignant neoplasms.
Identifying the tissue of origin (TOO) in these tumors allows for more specific treatment and improves outcomes.
However, primary classification remains a challenge in many cases. We evaluated the ability of a microarray-based
gene expression test to identify the TOO in tumor specimens from 21 patients with a diagnosis of CUP.
Methods: The Pathwork® TOO Test was used to measure gene expression patterns for 1550 genes; these were
compared for similarity to patterns from 15 known tissue types.
Results: The TOO Test yielded a clear single positive call for the primary site in 16 of 21 (76%) specimens and was
indeterminate in 5 (24%). The positive results were consistent with clinicopathologic suggestions in 10 of the 16
cases (62%). In the remaining six cases the positive results were considered plausible based on clinical information.
Positive calls included colorectal (5), breast (4), ovarian (3), lung (2), and pancreas (2). The TOO Test ruled out an
average of 11 primary tissues in each CUP specimen.
Conclusion: The Pathwork TOO Test reduced diagnostic uncertainty in all CUP cases and could be a valuable
addition or alternative to current diagnostic methods for classifying uncertain primary cancers.
Background
Patients with carcinoma of unknown primary (CUP)
present with metastatic disease for which the tissue of
origin (TOO) cannot be identified. About 3%-5% of all
diagnosed cancers are classified as CUP [1-4] and an
estimated 31,490 new cases of cancer of unspecified pri-
mary sites were diagnosed in the United States in 2008
[5]. Prognosis of patients with CUP is usually poor with
empiric treatment. Median survival is 3-9 months even
with newer combination regimens [4,6-10]. It has been
shown that survival can improve if the primary site is
identified and specific therapy is instituted [11,12] as
currently recommended in therapeutic guidelines [4,13].
Unfortunately, primary tumor detection remains chal-
lenging. While serum tumor markers, imaging tests, and
immunohistochemistry (IHC) panels can help identify
the tissue of origin, the primary site is identified in
fewer than 30% of those who present initially with
occult primary tumor [13-15]. Furthermore, some posi-
tive findings can be misleading [2,16]. For example, in
three large IHC studies (>50 specimens) of known meta-
static specimens, IHC findings failed to agree with the
site of origin in about one third of cases [17-19]. In
addition, CUP diagnostic workups today are all too
often time-consuming, expensive, and unsuccessful
[13,20].
Recently, gene expression tests to classify tumors by
tissue origin have been developed. These tests employ
microarrays or real-time reverse transcriptase polymer-
ase chain reaction (RT-PCR) to measure mRNA tran-
scripts [21-29] and one uses a microarray to quantify
microRNAs [30]. Thus far, performance of these expres-
sion tests has been assessed mainly by challenges against
panels of tumors from known primary sites; however,
the panel composition has varied widely in terms of spe-
cimen number, specimen handling, tissue types
included, number of replicates for each tissue type, and
the proportions of metastatic and poorly differentiated
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in the range of 76% to 89%. Although these performance
studies are necessary and important, a challenge with
actual CUP specimens is needed to gauge the true clini-
cal value of these tests. Designing such a study is inher-
ently difficult because CUP specimens, by definition,
lack a reference diagnosis. Only recently have expres-
sion-based tissue test results in CUP specimens been
reported [31-33].
The Pathwork® TOO Test (Pathwork Diagnostics,
Sunnyvale, California, U.S.) is a microarray-based gene
expression diagnostic test for determining the similarity
of a tumor specimen to 15 known tissue types. The test
interprets the expression of 1550 genes in each speci-
men by applying normalization and classification algo-
rithms to gene expression data from a microarray. The
similarity of each tumor specimen’s gene expression pat-
tern is compared to the 15 tissues covered by the test.
For each specimen, the pathologist receives a report
with 15 separate scores that reflect the similarity of the
specimen’s gene expression profile to each of the refer-
ence tissues. Evaluation of the TOO Test found highly
reproducible results across four laboratories [28] and in
a blinded multicenter evaluation of 547 known primaries
(47% metastatic, 53% poorly differentiated or undifferen-
tiated primaries), the test had an overall agreement of
87.8% with the pathologist-issued diagnosis [29].
In this study, we evaluated the clinical utility of the
TOO Test in identifying the primary site in specimens
from patients diagnosed with CUP. The aims were to
evaluate the test’s ability to issue a clear positive call in
classic CUP specimens, to check the consistency of the
test results against a short-list of diagnostic possibilities
based on clinicopathology, and to estimate the potential
added clinical value of positive and negative results in
guiding management.
Methods
Study Design
This was a retrospective study of tumor specimens from
21 patients diagnosed with CUP. Fresh-frozen specimens
were obtained from tissue banks at the Mayo Clinic and
the University of Pittsburgh. The specimens had been
archived between January 1998 and December 2006. Spe-
cimen processing and microarray scanning were per-
formed at each site. Data files were analyzed by Pathwork
Diagnostics and a report was generated. Electronic test
scores were sent to study site pathologists who were
blinded to the associated patient’s clinicopathologic
information. The pathologists used predetermined cutoffs
to make final expression test calls of positive or indeter-
minate for each specimen. The code was then broken
and expression results were compared with the available
clinical, radiologic, pathological, and therapeutic findings
as a basis for conclusions about the consistency, plausi-
bility, and potential added clinical value of TOO Test
results. The study was conducted under protocols
approved by the institutional review boards of each
institution.
Case Selection and CUP Definition
Cases were first identified for possible inclusion in the
study by manual and electronic searching of tissue bank
archives. Search terms and diagnostic codes included
“CUP,”“ unknown,” and “uncertain.” Specimens with a
high number of IHC results were also selected for
review.
Most patients whose specimens were included had
received a complete history, physical, and full clinical,
laboratory, imaging, and pathologic workups, including
standard histologic and IHC examination, prior to their
designation as CUP. Specimens from patients from the
Mayo Clinic (n = 11) were also evaluated by a panel of
stains to rule out certain subsets of malignancies. These
stains included but were not limited to: keratins or
epithelial membrane antigen, S-100 or HMB45, LCA
(CD45), chromogranin or synaptophysin, CK20, CK7,
thyroid transcription factor 1 (TTF-1), and CDX-2.
Directed evaluation of symptomatic areas and targeted
testing based on history or symptoms (e.g., abdominal
CT, mammogram in women, colonoscopy in cases of
liver metastasis) were undertaken in Mayo Clinic
patients. Specimens designated as biopsy-proven carcino-
mas (e.g., carcinomas, adenocarcinomas, and mucinous
adenocarcinomas) with varying levels of differentiation
and from various sites were included. Available treatment
data and performance status for Mayo Clinic patients
were compiled but not required for inclusion.
The minimum inclusion criteria for screened specimens
were: (1) characterization as CUP after well-documented
pathologic examination; (2) availability of frozen specimen
block with histologic verification of at least 60% tumor
representation and less than 20% necrosis; (3) availability
of medical records with core demographics as well as a
clinicopathologic report including a summary of any nar-
rowed diagnostic possibilities. Any specimens assigned a
definitive single tissue type or included in previous studies
reporting performance of the TOO Test [28,29] were
excluded.
Gene Expression Test
The study pathologist at each site checked necrosis and
tissue viability in a section from each frozen tissue block
and then RNA was extracted and processed according
to previously published methods [28]. Spectrophotome-
try was used to assess adequate total RNA concentration
and purity. In general, the protocol for processing the
RNA, amplifying and labeling fragments, hybridizing
material on the microarray, and scanning is similar
to the standard Affymetrix protocol for 3’-based gene
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tary Pathwork Pathchip™ or an Affymetrix GeneChip
array on Affymetrix 3000 or 3000Dx GeneChip instru-
mentation (fluidics station and scanner) and the Gene-
Chip operating software to generate gene expression
data (.CEL files). Raw data files were submitted to Path-
work Diagnostics for automated analysis and report gen-
eration (Figure 1).
The Pathwork TOO Test algorithm transforms probe-
level intensity data into gene expression values, performs
data verification, and standardizes expression values
using a 121-gene standardization method whose perfor-
mance has been previously described [28,34]. Expression
levels of the 1550 genes for each specimen are then
compared in pairwise fashion with the pre-established
gene profiles for each of the 15 tissues on the test panel.
The results are presented on an electronic report as 15
separate Similarity Scores (SS), one for each tissue on
the panel.
Data Analysis
Coded electronic reports with SS and no patient infor-
mation were sent to investigators, who used pre-estab-
lished cutoffs to make a final determination about each
tissue type as positive or indeterminate. The SS for each
of the 15 tissue types ranged from 0 (very low similarity)
to 100 (very high similarity). Per cut-offs determined
before the study, a SS of 30 or above indicated the pre-
sence of a given tissue in the specimen, a SS of 5 or less
indicated the absence of a given tissue in the specimen,
and a SS between 5 and 30 was considered indetermi-
nate [28,29].
For each specimen, the final TOO Test result was
compared with available clinical, laboratory, and imaging
results for that specimen and a determination was made
about the overall consistency of the TOO Test positive
result with the clinicopathologic suggestions. Given the
challenging nature of CUPs, inconsistencies were
expected. In some inconsistent cases, investigators eval-
uated the plausibility of TOO Test results by re-examin-
ing the patient file and, in some cases, performing
additional IHC analysis (CDX2 stain in two cases).
Investigators also performed a case-by-case review to
determine the consistency of negative tissue calls with
the clinicopathologic suggestion.
Results
Patient and Tumor Characteristics
Characteristics for individual patients from Mayo (n = 11)
and the University of Pittsburgh (n = 10) are detailed in
Table 1. Most patients were in the age range of 60-69
(n = 6) or 70-79 years of age (n = 7). The majority of
patients (15 of 21) were female. Tumor specimens were
taken from over a dozen different biopsy sites. Most cases
were described as having a stage IV or metastatic tumor.
Most specimens were characterized morphologically as
poorly differentiated (n = 13) or moderately differentiated
(n = 7).
Tumor IHC Analysis
A total of 49 unique IHC markers were employed in an
attempt to identify the origin of the tissue in these 21
specimens. An average of six IHC tests were performed
on each specimen (range: 0 to 13) and 12 of the 21 spe-
cimens received at least seven different IHC staining
tests including those targeting proteins known to be
useful in predicting tissue type (e.g., CK7, CK20, ER,
Figure 1 Tissue of Origin Test workflow and results.R N Af r o m
frozen tissue is extracted, amplified, and biotin-labeled before
hybridization to a Pathchip™ microarray. Gene expression data are
then analyzed and a report indicating the studied tissue’s molecular
similarity to established profiles for 15 tissues of origin is produced.
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in Table 2.
TOO Test Results
The Pathwork TOO Test gave a positive result for a sin-
g l et i s s u ei n1 6( 7 6 % )o f2 1C U Ps p e c i m e n s( T a b l e2 ) .
The identified primary sites included colorectal (5),
breast (4), ovary (3), lung (2), and pancreas (2). The TOO
Test was indeterminate in five cases (24%) (Figure 2).
The average SS in positive calls was 66.4 while the aver-
age highest SS in indeterminate calls was 23.0.
The TOO Test positive results were consistent with
clinicopathologic suggestions in 10 of the 16 cases (62%).
For example, in Case 3 the TOO Test yielded a positive
ovarian call, thus confirming one of the two main tissues
types under consideration (breast vs. ovarian). In Case 4,
the TOO Test pointed to a colorectal origin while the
pre-existing clinicopathologic data (based on colono-
scopy, mammogram, abdominal CT, and 10 IHC stains)
hinted at, but did not confirm, a gastrointestinal (GI) ori-
gin. In five of seven specimens called positive for GI ori-
gin (5 colorectal, 2 pancreas), the TOO Test result was
not unexpected given the pre-existing clinical differential.
Overall, six cases of unexpected positive TOO Test
results were produced. There were no obvious instances
of TOO Test error or high unlikelihood based on all
existing patient information (e.g., a prostate call in a
female patient, a sarcoma or melanoma call for a histo-
logically confirmed adenocarcinoma). Also, in many
cases, tissue types under active consideration were
“ruled out” based on negative results in expression test-
ing. In Case 6, for example, where the patient was
strongly suspected of having either a primary lung or
thyroid carcinoma due to positive TTF-1 staining, the
TOO Test result of breast carcinoma, while unexpected,
had not been absolutely ruled out by clinical factors.
Importantly, TTF-1 positivity has been reported in a
small percentage of breast and colon carcinomas
[35,36]. Further, the TOO Test gave negative Similarity
Scores for both lung (SS = 3.8) and thyroid (SS = 1.1).
Similarly, in Case 2 a diagnosis of renal cell carcinoma
was originally suspected but the TOO Test call of color-
ectal carcinoma was not improbable and the TOO Test
also provided a negative kidney signal (SS = 0.6). Immu-
nostain for CDX2 performed during this study and not
Table 1 Patient characteristics
Case
No.
Age Gender Biopsy site Prior cancer
history
Morphology CUP treatment regimen
1 70-79 F Liver Breast Moderately-differentiated adenocarcinoma supportive care only
2 70-79 M Mesentery None Poorly-differentiated adenocarcinoma supportive care only
3 60-69 F Soft Tissue Breast Poorly-differentiated carcinoma supportive care only
4 50-59 F Peritoneum None Poorly-differentiated adenocarcinoma paclitaxel/carboplatin/
gemcitabine
5 80-89 F Bone Breast Poorly-differentiated carcinoma radiation
6 80-89 F Soft tissue None Moderately-differentiated carcinoma supportive care only
7 80-89 M Pleura Prostate,
Bladder
Moderately-differentiated adenocarcinoma supportive care only
8 60-69 F Peritoneum None Poorly-differentiated carcinoma paclitaxel/carboplatin
9 70-79 F Peritoneum Rectal Poorly-differentiated carcinoma supportive care only
10 50-59 F Peritoneum Ovarian Well-differentiated mucinous adenocarcinoma supportive care only
11 60-69 F Peritoneum Breast Poorly-differentiated carcinoma paclitaxel/carboplatin
12 50-59 F Right Femur N/A Metastatic, well-to- moderately differentiated
adenocarcinoma
N/A
13 50-59 F Left Femur N/A Metastatic, poorly-differentiated adenocarcinoma N/A
14 70-79 F Lymph Node N/A Metastatic poorly-differentiated adenocarcinoma N/A
15 70-79 F Lung (Upper
Lobe)
N/A Moderately-differentiated papillary adenocarcinoma N/A
16 60-69 F Omentum N/A Metastatic poorly-differentiated adenocarcinoma N/A
17 70-79 M Abdominal Wall N/A Metastatic poorly-differentiated adenocarcinoma N/A
18 70-79 M Right Groin N/A Metastatic adenocarcinoma N/A
19 40-49 M Colon/Omentum N/A Poorly-differentiated adenocarcinoma N/A
20 60-69 M Right Clavicle N/A Moderately-differentiated mucinous adenocarcinoma N/A
21 60-69 F Liver/Lymph
Node
N/A Liver: poorly-differentiated carcinoma
LN: metastatic poorly-differentiated carcinoma
N/A
N/A = not available
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Immunohistochemistry Results Tissue of Origin (TOO) Test results
Case
No.
Negative Positive Suspected tissues
based on
clinicopathology
TOO result TOO
SS
Rule
out
tissues
Consistent Management
Value
1 BRST-2, CK20, TTF-1, ER,
PR, Her2/neu
CK7 Pancreas, Breast,
Upper GI
Indeterminate 22.1 8 ––
2 PSA CK20, CK7, CDX2* Kidney Colorectal 83.7 14 No* Yes
3 BRST-2, CK20, TTF-1, ER,
PR, Her2/neu
CK20, CK7, WT1 Ovary or Breast Ovary 87.6 14 Yes Yes
4 chromogranin,
synaptophysin, calretinin,
TTF-1, PR
CK20, CK7, CDX-2, CK5/6,
MOC31, ER, CEA
GI Primary,
Colorectal
Colorectal 81.8 13 Yes Yes
5 CDX-2, CD31, CK20,
Melan A, S-100, TTF-1
AE1/AE3, CK7 Renal cell carcinoma Indeterminate 24.7 11 ––
6 Thyroglobulin TTF-1 Lung, Thyroid Breast 61.2 12 No* Yes
7 CK20, PSA, TTF-1 CK7, AE1/AE3, keratin
903, p63
Lung Indeterminate 23.6 8 –
8 BRST-2, CD10, CD45, C-kit CDX-2, CAM5.2, CK20,
CK7, Keratin
Colorectal Colorectal 64.1 12 Yes Yes
9 CK20, CK7, TTF-1, ER, PR Colorectal, Ovary Lung 35.5 10 No* Yes
10 CDX-2*, CK20, CK7 Colorectal, Ovary Colorectal 71.2 13 Yes Yes
11 ER, PR, Her2/neu, BRST-2,
CDX-2, CK20
CK7, p53, WT1 Breast, Ovary Ovarian 86.6 14 Yes Yes
12 chromogranin,
synaptophysin, surfactant,
TTF, CK20, LCA, CA-125,
Her2/neu
ER, PR, monoclonal CEA,
focal CK7
Breast, Ovary, Uterine Breast 96.4 14 Yes Yes
13 Her2/neu, PR estrogen receptor (10%
cells staining at 1+)
Breast Breast 95 14 Yes Yes
14 HMB45, Tyrosinase,
Melan-A, RCC, ER
CK7, AE1/AE3, CAM 5.2,
TTF, S100, surfactant
protein, CK20; weak
CDX-2
Lung Ovarian 87.5 13 No* Yes
15 EGF-R Lung Lung 66.9 12 Yes Yes
16 LeuM1, S100 PLAP, CA-125,
monoclonal CEA
Pancreas, Ovary Pancreas 39.5 11 Yes Yes
17 PSA, neuroendocrine
markers, S100
mucicarmine, CEA,
cytokeratin
Colon, Prostate,
Stomach, Lung
Pancreas 37.3 10 No* Yes
18 PSA, TTF, calretinin,
thrombomodulin, P63
CK7, CK20, monoclonal
CEA, CDX-2
Esophagus, Stomach,
Pancreas, Biliary
Breast 36.1 10 No* Yes
19 smooth myo actin,
desmin, S100, HMB-45,
CD34, chromogranin, CK7
focal C-kit, focal
synaptophysin, focal
CK20, mucicarmine, PAS
Colon Colorectal 31.5 8 Yes Yes
20 Not available Not available None Indeterminate 24 9 ––
21 mucicarmine, HepPar,
alpha-fetoprotein,
synaptophysin
CEA monoclonal/
polyclonal, Cam-5.2, AE1
Liver,
Cholangiocarcinoma
Indeterminate 20.7 9 ––
* Still a plausible primary call given the overall patient presentation and clinicopathologic findings; see text for discussion.
SS: Similarity Score; AE: cytokeratin; BRST: Breast; C-kit: cytokine receptor CD117; CA-125: cancer antigen 125; Cam 5.2: anti-cytokeratin; CD: cluster of
differentiation; CDX: an intestine-specific transcription factor; CEA: carcinoembryonic antigen; CK: cytokeratin; ER: estrogen receptor; HepPar: hepatocyte paraffin;
Her-2/neu: human epidermal growth factor receptor 2; HMB-45: human melanoma black; LeuM1: a granulocyte-related differentiation antigen; P53: tumor protein
53, a transcription factor; P63: a P53-related nuclear protein; PAS: periodic acid Schiff stain; PLAP: placenta-like alkaline phosphatase; PR: progesterone receptor;
PSA: prostate-specific antigen; RCC: renal cell carcinoma marker; S-100: a neuroectodermal antigen; TTF-1: thyroid transcription factor-1; WT1: Wilms’ tumor
protein-1
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ing a colorectal origin. On average, the TOO Test ruled
out 11 tissue types per case, including in the indetermi-
nate cases. In cases with a positive call, the average
number of tissue types ruled out (i.e., SS <5) was 12
while the average in indeterminate calls was 9.
Discussion
For patients presenting with uncertain primary tumors
and who do not have a primary site identified even after
exhaustive investigation empiric chemotherapy is rarely
successful and often quite intolerable [7-9]. Better survi-
val is achieved when tissue-specific treatment strategies
are utilized [11,12,33]. Thus, availability of a test that
identifies the tissue of origin would increase the chances
of a patient receiving a more targeted and less toxic
therapy. Depending on how such a test is integrated
into the workup of uncertain primaries, it may also
reduce the overall time and expense associated with the
hunt for a primary tumor. In addition, as new tissue-tar-
geted therapies are expected to be introduced, correct
identification of the primary site will become even more
important in guiding optimal patient management.
Recently, we reported that the Pathwork Tissue of
Origin test showed robust performance in a large valida-
tion study with 547 tumors of known origin [29]. We
now have evaluated the performance of this test in a
cohort of 21 CUP cases. In this cohort the Pathwork
TOO Test was able to identify a probable single primary
site in 16 (76%) of the cases. These results suggest that
the TOO Test can significantly reduce diagnostic uncer-
tainty in patients with CUP.
Three recent studies have reported on gene expression
profiling as a strategy to determine TOO in patients
with CUP [31-33]. Two of these studies employed a
microarray-based 495-gene-expression classifier (Cup-
Print, Agendia, Amsterdam, NED), which gave a confi-
dent and clinically valuable result in 14 (64%) of 22
CUPs from one study [32] and a clinically feasible result
in 18 (86%) of 21 CUPs from the other study [31]. The
third study evaluated a 10-gene RT-PCR-based expres-
sion assay (Veridex, La Jolla, CA USA) and identified a
TOO in 23 (62%) of the 37 specimens classified as CUP
after IHC analysis [33]. Thus, expression tests with
widely varying designs and features (e.g., number/types
of genes; algorithm strategies; training set size; specimen
Figure 2 Distribution of tumor types in 21 CUPs. The Tissue of Origin Test called the majority of specimens definitively positive for a single
tumor type; in the indeterminate calls, the TOO Test ruled out an average of nine tissue types per specimen.
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have recently demonstrated an ability to issue a classifi-
cation for a majority of CUPs.
This general uniformity in call rates for identifying a
TOO in CUP patients among the various expression tests
(i.e., 62%-86%) does not necessarily imply a uniformity of
call accuracy or assay range. By definition, the gold stan-
d a r df o rt u m o rc a l l si nC U Pc a s e si su n k n o w a b l e .T h u s ,
accuracy in tissue identification can only be evaluated
with the use of a large and diverse set of known tumor
specimens. This type of evaluation is needed before any
projections can be made about a test’s clinical diagnostic
value–much less its potential impact on therapy choices
and outcome–in the setting of CUP. For example, in one
of the studies cited above [32], a parallel analysis of 84
tumors with known origin revealed total assay accuracy
of 83%; however, the test misclassified 7 of 11 lung
tumors and 3 of 3 pancreas tumors. Thus, if we extrapo-
late these results to CUP specimens, a large number of
CUP tumors with lung or pancreas origin could yield a
positive, albeit incorrect, tissue identification. Due to the
small number of studied samples (in particular of the
lung and pancreas groups) it is not possible to determine
the performance of that test for individual tissue types.
This same assay showed an accuracy of 87% in a previous
study with 119 tumor samples; however, some tissue
types were represented by only one or two specimens
(e.g., breast, adrenal) [27]. The 10-gene RT-PCR assay
showed an accuracy of 76% in a set of 48 metastatic sam-
ples [26]. Importantly, in a less rigidly defined set of 120
CUP specimens analyzed with the RT-PCR assay [33],
this test could not yield a result (due to insufficient
mRNA quality or yield) or failed to assign a TOO (per-
haps due to a limited 6-tissue panel) in 48% of the cases.
When the Pathwork TOO Test was validated in a large
multicenter study (n = 547), of poorly differentiated and
undifferentiated primary cancers and metastatic tumors,
it showed an overall sensitivity (positive percent agree-
ment with reference diagnosis) of 87.8% for the 15 tissues
of origin included in the panel [29]. In this validation
study, each of the 15 different tissue sites was represented
by at least 25 specimens. These performance characteris-
tics in known tissues must be considered when assessing
the likelihood of expression test accuracy in CUP cases.
Our study has several limitations, chief among them
the lack of a gold standard for comparison. This inabil-
ity to confirm accuracy, which is unavoidable in CUP
diagnostic studies, only heightens the importance of
quality and rigor in the associated clinical and patholo-
gical investigations. In this study, patients and CUP spe-
cimens were characterized in clinics with extensive
experience in oncology workups. Full histories, imaging
results, lab records, and pathology reports (including an
average of six IHC performed in each case) were
available before the CUP diagnosis was issued. Thus,
within the inherent constraints of CUP study design,
this study provides a fair measure of test performance–
certainly at least as fair as any of the seminal validation
studies of IHC itself [17-19]. Another limitation of this
study was its small size. This is related to the difficulty
in finding well-characterized fresh-frozen CUP speci-
mens. Using frozen tissue as a basis for initial CUP per-
formance testing makes sense since it yields more intact
mRNA [37]; however, we recognize that it is necessary
to validate the TOO Test with formalin-fixed paraffin
embedded (FFPE) specimens in order to allow the test
to be applied widely in non-research clinical settings.
Given the absence of a gold standard to evaluate CUP
assay performance, a surrogate marker of accuracy uti-
lized by prior studies has been the correlation of the
TOO prediction with existing clinicopathologic informa-
tion [31-33,38]. In our study, 10 cases show consistency
with the clinicopathologic-based differential diagnosis
(Table 2) and in six cases the test’s suggested diagnosis
was inconsistent. Review of cases where TOO Test posi-
tive results were not consistent with IHC and/or tenta-
tive clinical suggestions sheds further light on the
trustworthiness of gene expression profiles. None of
these six TOO Test results were deemed implausible or
in absolute contradiction to any known clinicopatholo-
gic findings. Even the TOO Test call of breast cancer in
a male (Case 18), while surprising, cannot be considered
patently incorrect given current estimates of approxi-
mately 2000 such new cases in the U.S. every year with
a rising incidence [39] and also considering reports of
male breast cancer presenting as CUP [40]. In addition,
the accompanying TOO Test negative results add
weight to the plausibility of surprising positive calls by
ruling out several of the originally suspected primaries.
In fact, the availability of “rule outs” is a unique feature
of TOO Test design that may eventually prove valuable
in case management; other tests provide the result of
the most molecularly similar tumor but do not report
information that allows ruling out specific tissue types.
Thus, although six of the TOO Test results were unex-
pected, given the published performance characteristics
of the test and recalling the performance deficits of IHC
as cited previously, they were still clinically plausible
TOO sites. Based on the overall clinical contributions of
TOO Test results, we estimated that the expression test
would have helped to inform patient management deci-
sions in the majority of cases (Table 2): definitively in
the 16 positive cases by identifying a single primary site,
and to varying degrees in the five indeterminate cases
by eliminating potential primary sites.
Another measure of the clinical relevance of TOO
identification is the ability to evaluate response to therapy
in those tumors that were treated with tissue-specific
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reported that patients with a molecular signature of
colon carcinoma showed better response to colorectal-
specific therapies than to empiric CUP therapy [33].
Unfortunately, the size of our study and the unavailability
of full outcome and treatment information for all 21
patients make it impossible for us to quantify how the
expression results might have translated into changed
therapy or improved outcomes. However, review of the
treatment data available for about half of the cases indi-
cated that most patients got the type of supportive care
with or without empiric chemotherapy that is typical in
CUP [4,7-10]. Of the 11 Mayo patients, for example, four
received at least 4 cycles of chemotherapy and one
received radiation therapy (4 radiation sequences, 800
cGy). Many of these patients likely would have received a
more tissue-specific therapy if a trusted expression test
result had been available at presentation. In Case 11, for
example, one of the options for more ovarian-focused
chemotherapy might have been given instead of pacli-
taxel/carboplatin if the TOO Test result of ovarian can-
cer had been available. In Case 6, doxorubicin and
paclitaxel might have been given rather than only sup-
portive care if the TOO Test result supporting a breast
origin had been known. Similarly, in Cases 4 and 8,
patients might have received bevacizumab instead of a
broad-based chemotherapy (paclitaxel/carboplatin with
or without gemcitabine) if the TOO Test result indicat-
ing colorectal cancer had been available at the time of
diagnosis.
Recently, based on retrospective and prospective ana-
lyses [12,33], some researchers have already advocated
using expression profiles to guide targeted therapy in
patients with colorectal cancer profiles. Such changes in
CUP therapy directed by molecular profiling might rea-
sonably be expected to equate to improvement in out-
comes, but this important hypothesis needs to be tested
in prospective studies. Only carefully designed studies
will reveal whether tumors originally deemed CUPs
respond to specific treatment in the same manner as
more well-differentiated tumors of the same tissue type.
It may be, for example, that hard-to-identify CUP-like
tumors actually possess distinct genetic/phenotypic
aberrations (while maintaining tissue-specific expression
traits) that limit their susceptibility to therapies tested
only in non-CUP tumors [41,42]. In this context,
because of the TOO Test’s high accuracy in poorly dif-
ferentiated tumor types and also because of the high
number of genes assayed, this test may be particularly
well suited not only to classifying tissue origin in CUP
but, in the future, to providing information about the
tumor’s susceptibility to specific therapies.
Conclusions
The Pathwork TOO Test shows clear promise in identi-
fying tissue origin in cases currently classified as CUP.
The test could be a valuable addition or alternative to
current diagnostic methods for classifying uncertain pri-
mary cancers. Further studies evaluating the impact of
gene expression-based test results on therapy choice and
treatment outcome for CUP patients are warranted.
Abbreviations
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